CYCLACEL PHARMACEUTICALS HIGHLIGHTS PUBLICATION OF PRECLINICAL DATA SHOWING THAT PLOGOSERTIB IS ACTIVE IN A HARD-TO-TREAT SUBTYPE OF LIVER CANCER

         - Fibrolamellar hepatocellular carcinoma (FLC) has no approved treatment and
         occurs mostly in adolescents and young adults -

KUALA LUMPUR, Malaysia, July 07, 2025 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; “Cyclacel” or the “Company”), a biopharmaceutical company developing innovative cancer medicines, highlighted a publication from independent investigators titled, “DNAJ-PKAc fusion heightens PLK1 inhibitor sensitivity in fibrolamellar carcinoma,” published online in the journal Gut, a leading, peer-reviewed medical journal focused on gastroenterology and hepatology.¹ The authors of the study described in the publication reported that DNAJ-PKAc, a fusion oncoprotein known to drive FLC progression, makes the cancer sensitive to treatment with plogosertib.

Read more at globenewswire.com